Moneycontrol
Get App
Last Updated : Nov 06, 2015 04:58 PM IST | Source: Moneycontrol.com

Neutral on Sun Pharmaceuticals : Reliance Securities

Reliance Securities has a neutral view on Sun Pharmaceuticals, in its November 04, 2015. research report.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More
Reliance Securities's report on Sun Pharmaceuticals

Taro’s 2Q results is reflective of 6th successive quarter of declining volumes (adjusted for price benefits in 2QFY15) led by customer consolidation, increasing competitive intensity and overall industry consolidation. Taro is a key strategic asset for Sun and contributes significantly to the latter’s margins. Steady build up of cash and ANDA pipeline are medium term positive which allow for strategic flexibility. However, owing to structural headwinds in Sun’s base business, we
maintain NEUTRAL with a Fair Value of Rs 940.

Outlook and Valuation
The continuous decline in performance remains in-line with our expectation despite the price rise taken by the company in wide array of products on the back of shrinking volume growth. While management asserts that price adjustment is now fully reflective in the sales, we remain less optimistic. Assuming best case scenario of 5 launches in FY16E, we expect 50% to be in commoditized oral category making it difficult for Taro to maintain high base growth rate. We forecast Taro to report 7% revenue CAGR over FY15-18E. We maintain NEUTRAL with a Fair Value of Rs 940, says Reliance research report.

For all recommendations, click here

Disclaimer:
The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.


Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Nov 6, 2015 04:58 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant